Who signed the Aspire Biopharma (ASBP) Form 8-K related to the investor presentation?

The Form 8-K was signed on behalf of Aspire Biopharma Holdings, Inc. by Kraig Higginson . He is identified as the company’s Chief Executive Officer , authorizing the report that furnishes the investor presentation.

Aspire Biopharma (NASDAQ: ASBP) readies August investor deck

Q: How is the new Aspire Biopharma (ASBP) investor information provided to the market?

The investor information is provided through an investor presentation furnished as Exhibit 99.1 to a Form 8-K. This is characterized as a Regulation FD disclosure, meant to share information broadly with the market.

Q: When is the Aspire Biopharma (ASBP) investor presentation dated?

The Aspire Biopharma investor presentation is dated August 19, 2026 . On that same date, the company indicated its intention to distribute the presentation and furnished it to investors as Exhibit 99.1 to the Form 8-K report.

Q: On which exchange does Aspire Biopharma Holdings, Inc. (ASBP) trade and under what symbols?

Aspire Biopharma’s common stock trades on The Nasdaq Stock Market LLC under the symbol ASBP . Its warrants, each exercisable for one share of common stock, trade on the same market under the symbol ASBPW .

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. (ASBP) reported that it plans to distribute an investor presentation on August 19, 2026. The company furnished this presentation as Exhibit 99.1 to provide additional information to the market under a Regulation FD disclosure.

The common stock and public warrants of Aspire Biopharma Holdings, Inc. trade on The Nasdaq Stock Market LLC under the symbols ASBP and ASBPW, respectively. The report was authorized on behalf of the company by Chief Executive Officer Kraig Higginson.

Insights

Analyzing...

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Regulation FD, Emerging growth company, Inline XBRL

3 terms

Regulation FD regulatory

"Item 7.01 Regulation FD Disclosure On August 19, 2026, the Company intends"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"Cover Page Interactive Data File (embedded with the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

What did Aspire Biopharma Holdings, Inc. (ASBP) announce in this Form 8-K?

Aspire Biopharma Holdings, Inc. announced it intends to distribute an investor presentation dated August 19, 2026. The presentation is furnished as Exhibit 99.1, providing additional information to investors under a Regulation FD disclosure.

How is the new Aspire Biopharma (ASBP) investor information provided to the market?

The investor information is provided through an investor presentation furnished as Exhibit 99.1 to a Form 8-K. This is characterized as a Regulation FD disclosure, meant to share information broadly with the market.

When is the Aspire Biopharma (ASBP) investor presentation dated?

The Aspire Biopharma investor presentation is dated August 19, 2026. On that same date, the company indicated its intention to distribute the presentation and furnished it to investors as Exhibit 99.1 to the Form 8-K report.

On which exchange does Aspire Biopharma Holdings, Inc. (ASBP) trade and under what symbols?

Aspire Biopharma’s common stock trades on The Nasdaq Stock Market LLC under the symbol ASBP. Its warrants, each exercisable for one share of common stock, trade on the same market under the symbol ASBPW.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/19/2026 - 08:30 AM Accepted by SEC EDGAR 08/19/2026 - 08:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2026

Aspire Biopharma Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-41293

33-3467744

(State or other jurisdiction

of incorporation)

(Commission

File No.)

(I.R.S. Employer

Identification No.)

23150 Fashion Drive

Estero, FL 33928

(Address of Principal Executive Offices)

(415) 592-7399

(Registrant’s Telephone Number)

PowerUp Acquisition Corp.

188 Grand Street, Unit #195

New York, NY 10013

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ASBP	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock	ASBPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On August 19, 2026, the Company intends to distribute an investor presentation. A copy of the investor presentation is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Investor Presentation dated August 19, 2026
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.